3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
1
Interventions
Ipilimumab
101
pembrolizumab
94
Nivolumab
87
Cyclophosphamide
69
fludarabine phosphate
55
aldesleukin
52
Interleukin-2
39
Dacarbazine
35
Vemurafenib
31
fludarabine
30
trametinib
29
dabrafenib
29
Temozolomide
28
Whole-Body Irradiation
21
Aminolevulinic Acid
21
Carboplatin
20
CTLA-4 Antigen
20
Bevacizumab
20
Radiotherapy
19
Peripheral Blood Stem Cell Transplantation
19
Radiosurgery
18
Tacrolimus
17
Mycophenolic Acid
17
Paclitaxel
16
HhAntag691
16
3-ingenyl angelate
16
Busulfan
15
Introns
14
Antilymphocyte Serum
14
encorafenib
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
canakinumab
×
Dermatologic
×
Clear all
NCT03484923
2024-06-18
PLATforM
Novartis
Phase 2
Completed
196 enrolled
22 charts